ClinicalTrials.gg
Sign In
RecruitingNCT06816524Updated Nov 5, 2026

The Effects of Iron Treatment on Vaccine Immunogenicity in Kenyan Infants With Iron Deficiency

An interventional study of Iron syrup and Multivitamin syrup in Iron Deficiencies, sponsored by Nicole Stoffel. Recruiting at 1 site in Kenya. Open to participants aged 6 Months to 6 Months. Per ClinicalTrials.gov, last updated 2026-11-05.

Sponsored by Nicole Stoffel · Not applicable, Interventional, and Other

From the registry’s dates

  • Started Mar 2026; still recruiting 7 months later.
Updated Nov 5, 2026Now RecruitingFirst site in Kenya+6 moreGo to Updates ↓
Phase
Not applicable
Study type
Interventional
Enrollment
324
Allocation
Randomized
Ages
6 Months to 6 Months
Sex
All
01

Study summary

Malaria and iron deficiency cause a significant burden of disease in Africa. Iron deficiency (ID) might affect immune responses to vaccination.

In this double-blind randomized controlled trial, we aim to assess: (1) whether ID impairs R21/Matrix-M, Typhim VI and measles (MR) vaccine response, (2) whether iron treatment at time of vaccination improves vaccine response.

02

Conditions studied

  • Iron Deficiencies

Keywords

  • Iron deficiency
  • Vaccine immunogenicity
  • Malaria
  • Measles
03

In context

Iron Deficiencies

386 studies on the registry are indexed under Iron Deficiencies; 80 are open to participants now.

This study's planned enrollment of 324 is above the median of 99 across 301 interventional studies indexed under Iron Deficiencies.

Browse Iron Deficiencies studies →

Lead sponsor

Nicole Stoffel is the lead sponsor of 4 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

The criteria were revised on the registry on Nov 5, 2026. See what changed

Ages eligible
6 Months to 6 Months
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subject's caregiver is willing and able to give
  • Male or Female, 6 months (+/- 2 weeks) of age
  • Mother ≥15 years of age
  • Iron deficient (erythrocyte zinc protoporphyrin (ZnPP) >61 μmol/mol heme) or anemic ( (Hb) \<105 g/L)

Exclusion criteria

Exclusion Criteria:

  • Severely anemic ( \<70 g/L)
  • Hemoglobinopathies HbCC, HbSC, or HbSS
  • Malaria, Measles or Typhoid vaccination prior to enrollment
  • Medical condition that precludes study involvement
  • Iron supplementation 2 weeks before enrollment
  • Acute or chronic infection (e.g. )
  • Wasted (length for height z score of ≥-2) or underweight (weight for age z score ≥-2).
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anaemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
324 participants (estimated)

Study arms

  • Active comparator
    Iron treatment group

    daily multivitamin + daily iron syrup from age 6 to 10 months

    Dietary Supplement: Iron syrup · Dietary Supplement: Multivitamin syrup · Biological: R21-Matrix/M Vaccine (malaria vaccine) · Biological: Measles-Rubella vaccine

  • Other
    Control group

    daily multivitamin syrup from age 6 to 10 months

    Dietary Supplement: Multivitamin syrup · Biological: R21-Matrix/M Vaccine (malaria vaccine) · Biological: Measles-Rubella vaccine

Interventions

  • Dietary supplementIron syrup

    Iron syrup administered daily from 6 to 10 months of age.

  • Dietary supplementMultivitamin syrup

    Multivitamin syrup administered daily from 6 to 10 months of age.

  • BiologicalR21-Matrix/M Vaccine (malaria vaccine)

    R21-Matrix/M vaccine administered in 3 doses at 7, 8 and 9 months of age.

  • BiologicalMeasles-Rubella vaccine

    Measles-Rubella vaccine administered at 9 months of age.

06

What researchers measure

Primary outcomes

  1. NANP-specific IgG

    IgG antibodies targeting the NANP repeat region of the circumsporozoite protein (CSP)

    Time frame: At 10 months of age (1 month after the 3rd R21/Matrix-M dose)

  2. Anti-measles IgG

    IgG antibodies targeting measles antigen

    Time frame: At 10 months of age (1 month after MR vaccine administration)

Secondary outcomes

  1. Anti-typhoid IgG

    IgG antibodies targeting typhoid antigen

    Time frame: At 10 months of age (1 month after Typhim VI administration)

  2. C-terminal-specific IgG

    IgG antibodies targeting the C-terminal region of CSP

    Time frame: At 10 months of age (1 month after 3rd R21/Matrix-M dose)

  3. C-terminal-specific IgG

    IgG antibodies targeting the C-terminal region of CSP

    Time frame: At 9 months of age (1 month after the 2nd R21/Matrix-M dose)

  4. C-terminal-specific IgG

    IgG antibodies targeting the C-terminal region of CSP

    Time frame: At 8 months of age (1 month after the 1st R21/Matrix-M dose)

  5. NANP-specific IgG

    IgG antibodies targeting the NANP repeat region of CSP

    Time frame: At 9 months of age (1 month after the 2nd R21/Matrix-M dose)

  6. NANP-specific IgG

    IgG antibodies targeting the NANP repeat region of CSP

    Time frame: At 8 months of age (1 month after the 1st R21/Matrix-M dose)

  7. Full-length CSP-specific IgG

    IgG antibodies targeting the full-length CSP

    Time frame: At 10 months of age (1 month after the 3rd R21/Matrix-M dose)

  8. NANP-specific IgM

    IgM antibodies targeting the NANP repeat region of CSP

    Time frame: At 10 months of age (1 month after the 3rd R21/Matrix-M dose)

  9. NANP-specific IgA

    IgA antibodies targeting the NANP repeat region of CSP

    Time frame: At 10 months of age (1 month after the 3rd R21/Matrix-M dose)

  10. NANP-specific IgG4

    IgG4 antibodies targeting the NANP repeat region of CSP

    Time frame: At 10 months of age (1 month after the 3rd R21/Matrix-M dose)

  11. NANP-specific IgG3

    IgG3 antibodies targeting the NANP repeat region of CSP

    Time frame: At 10 months of age (1 month after the 3rd R21/Matrix-M dose)

  12. NANP-specific IgG2

    IgG2 antibodies targeting the NANP repeat region of CSP

    Time frame: At 10 months of age (1 month after the 3rd R21/Matrix-M dose)

  13. NANP-specific IgG1

    IgG1 antibodies targeting the NANP repeat region of CSP

    Time frame: At 10 months of age (1 month after the 3rd R21/Matrix-M dose)

  14. IgG avidity to measles antigen

    Avidity index for IgG binding to measles antigen

    Time frame: At 10 months of age (1 month after MR vaccine administration)

  15. IgG avidity to typhoid antigen

    Avidity index for IgG binding to typhoid antigen

    Time frame: At 10 months of age (1 month after Typhim VI administration)

  16. IgG avidity to NANP-specific CSP

    Avidity index for IgG binding to NANP CSP

    Time frame: At 10 months of age (1 month after the 3rd R21/Matrix-M dose)

  17. IgG avidity to C-terminal CSP

    Avidity index for IgG binding to C-terminal CSP

    Time frame: At 10 months of age (1 month after the 3rd R21/Matrix-M dose)

  18. Full-length CSP-specific IgG seropositivity

    Categorical (positive/negative)

    Time frame: At 10 months of age (1 month after the 3rd R21/Matrix-M dose)

  19. C-terminal-specific IgG seropositivity

    Categorical (positive/negative)

    Time frame: At 10 months of age (1 month after the 3rd R21/Matrix-M dose)

  20. C-terminal-specific IgG seropositivity

    Categorical (positive/negative)

    Time frame: At 9 months of age (1 month after the 2nd R21/Matrix-M dose)

  21. C-terminal-specific IgG seropositivity

    Categorical (positive/negative)

    Time frame: At 8 months of age (1 month after the 1st R21/Matrix-M dose)

  22. NANP-specific IgG seropositivity

    Categorical (positive/negative)

    Time frame: At 10 months of age (1 month after the 3rd R21/Matrix-M dose)

  23. NANP-specific IgG seropositivity

    Categorical (positive/negative)

    Time frame: At 9 months of age (1 month after the 2nd R21/Matrix-M dose)

  24. NANP-specific IgG seropositivity

    Categorical (positive/negative)

    Time frame: At 8 months of age (1 month after the 1st R21/Matrix-M dose)

Other outcomes

  1. Inhibition of Plasmodium falciparum sporozoite-invasion of HC-04 hepatic cells

    Exploratory in vitro assay on IgG functionality in lowest and highest responders

    Time frame: At 10 months of age (1 months after the 3rd R21/Matrix-M dose)

  2. Opsonic phagocytosis of CSP-coated beads by THP-1 cells

    Exploratory in vitro assay of IgG opsonization functionality in lowest and highest responders

    Time frame: At 10 months of age (1 month after the 3rd R21/Matrix-M dose)

  3. Antibody-dependent cellular cytotoxicity (ADCC) by natural killer (NK) cells

    Exploratory in vitro assay performed in lowest and highest responders

    Time frame: At 10 months of age (1 month after the 3rd R21/Matrix-M dose)

  4. Antibody levels against a panel of antigens associated with malaria exposure in the previous year

    Exploratory in all participants

    Time frame: At 7 months of age (baseline)

07

Study locations

1 of 1 sites recruiting
  • Msambweni District Hospital
    Msambweni, Kwale County 80404, Kenya
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2026 (actual). Primary completion is estimated for Dec 2027, 21 months after the start.

Of 76 non-industry interventional studies with no phase under Iron Deficiencies, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 26. This study's planned 21 months is above that.

Counting every sponsor, half of 88 studies reached it within 10 months; a quarter within 5 and three quarters within 26.

Start moved once since we started tracking on Sep 25, 2026: Jan 2026 → Mar 2026, on Nov 5, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Feb 4, 2025
First posted
Feb 10, 2025
StartActual
Mar 13, 2026was Jan 2026
Primary completionEst.
Dec 31, 2027
CompletionEst.
Apr 30, 2028
Last update
Nov 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Nov 5, 2026
Sites
1 site added — first site in Kenya
Show site
  • Msambweni District Hospital · Msambweni, Kenya
Nov 5, 2026
Start date
Jan 5, 2026→Mar 13, 2026 (actual)
Nov 5, 2026
Eligibility
2 inclusion criteria edited, 1 removed; 1 exclusion criterion edited, 1 added
What changed in the criteria
Inclusion criteria
  • EditedMother at least ≥15 years of age
  • EditedIron deficient (erythrocyte zinc protoporphyrin (ZnPP) >61 μmol/mol heme) or anemic (hemoglobin (Hb) <105 g/L)
  • RemovedWith or without anemia (anemia defined by Hb <110 g/L)
Exclusion criteria
  • AddedHemoglobinopathies HbCC, HbSC, or HbSS
  • EditedMalaria, Measles or Typhoid vaccination prior to enrollment
Nov 5, 2026
Primary outcomes
1 edited, 2 removed, 1 description edited
What changed in the outcomes
  • EditedantiAnti- full lengths CSPmeasles IgGTime frame: At 10 months of age (1 month after the 3rd R21/Matrix-M dose) → At 10 months of age (1 month after MR vaccine administration)
  • Removedanti- C-terminal CSP IgGTime frame: At 10 months of age (1 month after the 3rd R21/Matrix-M dose)
  • Removedanti-measles IgGTime frame: At 10 months of age (1 month after the first MR dose)
  • DescriptionNANP-specific IgG: how it is measured was reworded
Nov 5, 2026
Secondary outcomes
5 edited, 17 added, 8 removed, 51 more
What changed in the outcomes
  • EditedantiAnti- full lengths CSPtyphoid IgGTime frame: At 8 months age (1 month after the first R21/Matrix-M dose) → At 10 months of age (1 month after Typhim VI administration)
  • EditedantiNANP-CSPspecific IgATime frame: At 8 months age (1 month after the first R21/Matrix-M dose) → At 10 months of age (1 month after the 3rd R21/Matrix-M dose)
  • EditedantiNANP-CSPspecific IgMTime frame: At 8 months age (1 month after the first R21/Matrix-M dose) → At 10 months of age (1 month after the 3rd R21/Matrix-M dose)
  • Editedanti- C-terminal CSP-specific IgGTime frame: At 8 months age (1 month after the first R21/Matrix-M dose) → At 10 months of age (1 month after 3rd R21/Matrix-M dose)
  • Editedanti- C-terminal CSP-specific IgGTime frame: At 9 months age (1 month after the second R21/Matrix-M dose) → At 9 months of age (1 month after the 2nd R21/Matrix-M dose)
  • AddedC-terminal-specific IgGTime frame: At 8 months of age (1 month after the 1st R21/Matrix-M dose)
  • AddedFull-length CSP-specific IgGTime frame: At 10 months of age (1 month after the 3rd R21/Matrix-M dose)
  • AddedNANP-specific IgG4Time frame: At 10 months of age (1 month after the 3rd R21/Matrix-M dose)
  • AddedNANP-specific IgG3Time frame: At 10 months of age (1 month after the 3rd R21/Matrix-M dose)
  • AddedNANP-specific IgG2Time frame: At 10 months of age (1 month after the 3rd R21/Matrix-M dose)
  • AddedNANP-specific IgG1Time frame: At 10 months of age (1 month after the 3rd R21/Matrix-M dose)
  • AddedIgG avidity to measles antigenTime frame: At 10 months of age (1 month after MR vaccine administration)
  • AddedIgG avidity to typhoid antigenTime frame: At 10 months of age (1 month after Typhim VI administration)
  • AddedIgG avidity to NANP-specific CSPTime frame: At 10 months of age (1 month after the 3rd R21/Matrix-M dose)
  • AddedIgG avidity to C-terminal CSPTime frame: At 10 months of age (1 month after the 3rd R21/Matrix-M dose)
  • AddedFull-length CSP-specific IgG seropositivityTime frame: At 10 months of age (1 month after the 3rd R21/Matrix-M dose)
  • AddedC-terminal-specific IgG seropositivityTime frame: At 10 months of age (1 month after the 3rd R21/Matrix-M dose)
  • AddedC-terminal-specific IgG seropositivityTime frame: At 9 months of age (1 month after the 2nd R21/Matrix-M dose)
  • AddedC-terminal-specific IgG seropositivityTime frame: At 8 months of age (1 month after the 1st R21/Matrix-M dose)
  • AddedNANP-specific IgG seropositivityTime frame: At 10 months of age (1 month after the 3rd R21/Matrix-M dose)
  • AddedNANP-specific IgG seropositivityTime frame: At 9 months of age (1 month after the 2nd R21/Matrix-M dose)
  • AddedNANP-specific IgG seropositivityTime frame: At 8 months of age (1 month after the 1st R21/Matrix-M dose)
  • Removedanti- full lengths CSP IgGTime frame: At 9 months age (1 month after the second R21/Matrix-M dose)
  • Removedanti-CSP IgATime frame: At 9 months age (1 month after the second R21/Matrix-M dose)
  • Removedanti-CSP IgMTime frame: At 9 months age (1 month after the second R21/Matrix-M dose)
  • RemovedHaemoglobinTime frame: 6 months of age
  • RemovedHaemoglobinTime frame: 7 months of age
  • RemovedHaemoglobinTime frame: 8 months of age
  • RemovedHaemoglobinTime frame: 9 months of age
  • RemovedHaemoglobinTime frame: 10 months of age
  • …and 51 more, on the record history on ClinicalTrials.gov ↗
Nov 5, 2026
Contact
Study contact changed: g•••@rdm.ox.ac.uk · •••3770→l•••@pharma.ethz.ch · •••2070. See the current contact
Nov 5, 2026
Title
The Effects of Iron Treatment on Malaria and Measles Vaccine ResponseImmunogenicity in Kenyan Infants With Iron Deficiency
Nov 5, 2026
Show all 1 update
  1. Nov 5, 2026
    Not yet recruiting→Recruiting
    1 site added — first site in Kenya
    Show site
    • Msambweni District Hospital · Msambweni, Kenya
    Start date Jan 5, 2026→Mar 13, 2026 (now actual)
    Eligibility 2 inclusion criteria edited, 1 removed; 1 exclusion criterion edited, 1 added
    What changed in the criteria
    Inclusion criteria
    • EditedMother at least ≥15 years of age
    • EditedIron deficient (erythrocyte zinc protoporphyrin (ZnPP) >61 μmol/mol heme) or anemic (hemoglobin (Hb) <105 g/L)
    • RemovedWith or without anemia (anemia defined by Hb <110 g/L)
    Exclusion criteria
    • AddedHemoglobinopathies HbCC, HbSC, or HbSS
    • EditedMalaria, Measles or Typhoid vaccination prior to enrollment
    Primary outcomes 1 edited, 2 removed, 1 description edited
    What changed in the outcomes
    • EditedantiAnti- full lengths CSPmeasles IgGTime frame: At 10 months of age (1 month after the 3rd R21/Matrix-M dose) → At 10 months of age (1 month after MR vaccine administration)
    • Removedanti- C-terminal CSP IgGTime frame: At 10 months of age (1 month after the 3rd R21/Matrix-M dose)
    • Removedanti-measles IgGTime frame: At 10 months of age (1 month after the first MR dose)
    • DescriptionNANP-specific IgG: how it is measured was reworded
    Secondary outcomes 5 edited, 17 added, 8 removed, 51 more
    What changed in the outcomes
    • EditedantiAnti- full lengths CSPtyphoid IgGTime frame: At 8 months age (1 month after the first R21/Matrix-M dose) → At 10 months of age (1 month after Typhim VI administration)
    • EditedantiNANP-CSPspecific IgATime frame: At 8 months age (1 month after the first R21/Matrix-M dose) → At 10 months of age (1 month after the 3rd R21/Matrix-M dose)
    • EditedantiNANP-CSPspecific IgMTime frame: At 8 months age (1 month after the first R21/Matrix-M dose) → At 10 months of age (1 month after the 3rd R21/Matrix-M dose)
    • Editedanti- C-terminal CSP-specific IgGTime frame: At 8 months age (1 month after the first R21/Matrix-M dose) → At 10 months of age (1 month after 3rd R21/Matrix-M dose)
    • Editedanti- C-terminal CSP-specific IgGTime frame: At 9 months age (1 month after the second R21/Matrix-M dose) → At 9 months of age (1 month after the 2nd R21/Matrix-M dose)
    • AddedC-terminal-specific IgGTime frame: At 8 months of age (1 month after the 1st R21/Matrix-M dose)
    • AddedFull-length CSP-specific IgGTime frame: At 10 months of age (1 month after the 3rd R21/Matrix-M dose)
    • AddedNANP-specific IgG4Time frame: At 10 months of age (1 month after the 3rd R21/Matrix-M dose)
    • AddedNANP-specific IgG3Time frame: At 10 months of age (1 month after the 3rd R21/Matrix-M dose)
    • AddedNANP-specific IgG2Time frame: At 10 months of age (1 month after the 3rd R21/Matrix-M dose)
    • AddedNANP-specific IgG1Time frame: At 10 months of age (1 month after the 3rd R21/Matrix-M dose)
    • AddedIgG avidity to measles antigenTime frame: At 10 months of age (1 month after MR vaccine administration)
    • AddedIgG avidity to typhoid antigenTime frame: At 10 months of age (1 month after Typhim VI administration)
    • AddedIgG avidity to NANP-specific CSPTime frame: At 10 months of age (1 month after the 3rd R21/Matrix-M dose)
    • AddedIgG avidity to C-terminal CSPTime frame: At 10 months of age (1 month after the 3rd R21/Matrix-M dose)
    • AddedFull-length CSP-specific IgG seropositivityTime frame: At 10 months of age (1 month after the 3rd R21/Matrix-M dose)
    • AddedC-terminal-specific IgG seropositivityTime frame: At 10 months of age (1 month after the 3rd R21/Matrix-M dose)
    • AddedC-terminal-specific IgG seropositivityTime frame: At 9 months of age (1 month after the 2nd R21/Matrix-M dose)
    • AddedC-terminal-specific IgG seropositivityTime frame: At 8 months of age (1 month after the 1st R21/Matrix-M dose)
    • AddedNANP-specific IgG seropositivityTime frame: At 10 months of age (1 month after the 3rd R21/Matrix-M dose)
    • AddedNANP-specific IgG seropositivityTime frame: At 9 months of age (1 month after the 2nd R21/Matrix-M dose)
    • AddedNANP-specific IgG seropositivityTime frame: At 8 months of age (1 month after the 1st R21/Matrix-M dose)
    • Removedanti- full lengths CSP IgGTime frame: At 9 months age (1 month after the second R21/Matrix-M dose)
    • Removedanti-CSP IgATime frame: At 9 months age (1 month after the second R21/Matrix-M dose)
    • Removedanti-CSP IgMTime frame: At 9 months age (1 month after the second R21/Matrix-M dose)
    • RemovedHaemoglobinTime frame: 6 months of age
    • RemovedHaemoglobinTime frame: 7 months of age
    • RemovedHaemoglobinTime frame: 8 months of age
    • RemovedHaemoglobinTime frame: 9 months of age
    • RemovedHaemoglobinTime frame: 10 months of age
    • …and 51 more, on the record history on ClinicalTrials.gov ↗
    Contact Study contact changed: g•••@rdm.ox.ac.uk · •••3770→l•••@pharma.ethz.ch · •••2070. See the current contact
    Title The Effects of Iron Treatment on Malaria and Measles Vaccine ResponseImmunogenicity in Kenyan Infants With Iron Deficiency
    + 2 other changes: verification date and description

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06816524
Lead sponsor
Nicole Stoffel
Collaborators
Jomo Kenyatta University of Agriculture and Technology, University of Oxford - Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, Radboud University Medical Center, National Institute for Public Health and the Environment (RIVM)
Responsible party
Nicole Stoffel (Prof., ETH Zurich) — Sponsor-investigator
First posted
Feb 10, 2025
Start date
Mar 13, 2026
Primary completion
Dec 31, 2027 (estimated)
Completion
Apr 30, 2028 (estimated)
Last update
Nov 5, 2026

Study contacts

Nicole Stoffel, PhD
Contact
nicole.stoffel@hest.ethz.ch
044 632 83 93 ext. +41
Lara Del Curto, MSc
Contact
lara.delcurto@pharma.ethz.ch
0774212070 ext. +41
Nicole Stoffel, PhD
principal investigator · ETH Zurich

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Iron Deficiencies →

Other studies from this sponsor

Nicole Stoffel

Start the discussion